Oncolytics Biotech says pelareorep study triggers immune activation in liver cancer

Oncolytics Biotech flagged a Sept. 28, 2026 peer-reviewed publication on pelareorep’s immune effects in liver cancer, saying results were previously presented via the journal article and framed as support for its broader combination strategy.